Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Institutes of Health (NIH) has funded $718,136 grant to University of California San Francisco (UCSF) to discover and optimize oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals.
Subscribe to our email newsletter
Anacor has entered into partnership and works with UCSF to discover new antimalarial agents.
Anacor discovers, develops small-molecule therapeutics derived from its boron chemistry platform.
In addition Anacor works with Medicines for Malaria Venture (MMV) and has developed AN3661, a boron-based antimalarial compound that is currently in preclinical trials, and a funded research program to discover backup compounds for AN3661.
Anacor and MMV plan to conduct Phase 1 and Phase 2 proof of concept studies for AN3661, at which point GSK will have the option to license the program.